Investees
Investees
We are delighted to share our confirmed investees. The company profiles are listed in alphabetical order from A-Z. Click on the company logo to jump to the information.
BiomeBank
BiomeBank is a leading microbiome therapeutics company with a mission to restore human gut microbial ecology. BIOMICTRA,TM is the first approved donor derived microbiome therapy in the world (approved by TGA in 2022 for C.difficile infection).
BiomeBank’s CONSORTIOMETM drug development platform, leverages data from BIOMICTRA use in discovery trials in novel disease indications to create therapies disease specific cultured microbiome based therapies. The CONSORTIOME TM platform contains the ability to co-culture >100 of the most prevalent species covering >90% of known gene families in a healthy human gut microbiome into one drug substance.
Cultured therapy BB265 has been designed to treat ulcerative colitis and will enter a phase 1b/2a human study in 2025. Due to similar disease mechanisms, BB265 is expected to also have efficacy in treating Crohn’s disease. In addition, BB128 is being positioned for orphan disease indication and discovery trials are underway in 4 other novel disease indications.
Evithé Biotechnology
Evithé Biotechnology is a global bio-pharmaceutical company, specializing in the development of novel, patented botanical prescription drugs. The company has successfully produced new treatment modalities for inflammatory diseases, with a focus on Rheumatoid Arthritis.
Evithé Biotechnology's botanical drugs demonstrate superior performance over conventional pharmaceuticals, leveraging natural ingredients. The phase I clinical trial is affirming the safety of this innovative approach towards the treatment of a significant unmet need. The company is manufacturing at commercial scale in Australia, with a commitment to sustainable and FDA aligned processes.
Driven by a team of industry experts, Evithé Biotechnology is actively preparing for Phase II clinical trials, scheduled for 2025.
We anticipate launching our botanical drug into the $52 billion global Rheumatoid Arthritis market within the next six years. Additionally, we have a medical food product that is ready for licensing.
Immuron Limited | ASX:IMC
Immuron develops and commercialises orally delivered treatments for infectious diseases utilising proprietary technology based on polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum which have capability of producing highly specific immunoglobulins to any enteric pathogen.
Immuron has two commercial products – Travelan® and Protectyn® and four clinical programs: two Phase 2, one Phase 4, one pre-IND.
Travelan® (IMM-124E) contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin.
IMM-529 contains antibodies targeting three C. diff virulence components: Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach demonstrated in pre-clinical infection and relapse models: Prevention of primary disease (80% P =0.0052); Protection of disease recurrence (67%, P <0.01) and Treatment of primary disease (78.6%, P<0.0001; TcB HBC). IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.
Invion (ASX:IVX)
Invion (ASX: IVX) is a clinical stage company developing the next-generation Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion is undertaking its Ph I/II human trials on skin cancer this year and more trials to treat other cancers are scheduled over the next 12-24 months.
Pre-clinical results undertaken by Invion's research partners, the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, showed that the technology completely regressed a range of cancers, such as triple negative breast and ovarian cancers, stimulated the body's immune system to continue fighting the cancer and appeared to impede metastatic cancer.
Invion's lead drug candidate is INV043, a novel, patent protected photosensitiser, has the potential to work as a therapy and a diagnostic tool. Under a certain wavelength of red light, it selectively kills cancer cells and promotes an immune response with the potential to attack other related cancers. Under violet light, it causes tumours to fluoresce.
Nyrada (ASX:NYR)
Nyrada Inc (ASX:NYR) is a drug development company specialising in novel treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal. US incorporated, ASX listed, Australia headquartered, Nyrada's lead program is a first in class neuroprotection therapy for both traumatic brain injury (TBI) and stroke. Nyrada additionally has important scientific partnerships, including with the US Department of Defence (Walter Reed Army Institute of Research) and UNSW, Sydney.
PharmAust Limited
PharmAust is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND). Monepantel is a safe and potent inhibitor of the mammalian target of rapamycin (mTOR) pathway. The mTOR pathway has been shown to regulate the cellular “cleaning process” known as autophagy, where toxic proteins are broken down into macromolecules to be reused by the cell. This autophagic process is disrupted in most neurodegenerative diseases, including ALS. The company recently announced positive top-line results for monepantel in its Phase 1 MEND study in participants with ALS, was granted an Orphan Drug Designation (ODD) by the US FDA for monepantel for the treatment of ALS and monepantel was selected for inclusion in the prestigious HEALEY ALS Platform Trial at Massachusetts General Hospital.
